We are analyzing https://link.springer.com/article/10.1007/s00401-011-0803-5.

Title:
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts | Acta Neuropathologica
Description:
O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl DNA adducts such as those induced by alkylating agents. Loss of MGMT expression through transcriptional silencing by hypermethylation of its CpG island (CGI) is found in diverse human cancers including glioblastomas. Glioblastomas that have MGMT methylation respond to temozolomide, an alkylating agent, resulting in improved survival. Consequently, assessment of MGMT methylation has become a therapy response and prognostic indicator. However, it is not clear whether the region of the MGMT CGI commonly analysed is the critical region involved in transcriptional control. We measured methylation levels at each CpG site for the entire MGMT CGI using bisulfite modification and pyrosequencing, and compared them with MGMT mRNA expression in glioblastoma cell lines, xenografts and normal brain tissues (41 samples). Two critical regions were identified (DMR1 and DMR2). DMR2 encompasses the commonly analysed region and was always methylated when DMR1 was methylated. A luciferase reporter assay showed that substitutions of several specific CpG sites within DMR2 significantly attenuated the promoter activity of the MGMT CGI. Our results indicate that several CpG sites within DMR2 play a critical role in the transcriptional control of MGMT, making DMR2 the optimal target for methylation testing. However, given the highly variable patterns of MGMT methylation associated with transcriptional silencing observed in this region among the tumours in this study, methylation levels need to be measured at a number of individual CpGs within DMR2 to confidently predict transcriptional silencing and thus sensitivity to alkylating agents.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Careers
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, google, scholar, pubmed, cas, mgmt, methylation, cpg, methyltransferase, dna, human, glioblastoma, promoter, gene, region, dmr, omethylguaninedna, analysis, nucleosome, cancer, supplementary, island, silencing, site, transcriptional, methylated, expression, cgi, pyrosequencing, cell, lines, sites, pcr, transcription, start, acta, collins, ichimura, temozolomide, access, omethylguanine, mol, privacy, cookies, content, critical, alkylating, regions, quantitative, glioma,

Topics {✒️}

o6-methylguanine-dna methyltransferase gene o6-methylguanine-dna methyltransferase status multiple test-corrected p-values o6-methylguanine dna methyltransferase o6-methylguanine-dna methyltransferase month download article/chapter newly diagnosed glioblastoma methylation-related chromatin structure dna-encoded nucleosome organization jp/research/db/tfsearch o6-methylguanine methyltransferase p14arf/mdm2/p53 pathway cpg methylation-dependent repression high-performance liquid chromatography recurrent high-grade glioma luciferase assay results full article pdf related subjects dna repair protein poor dna methylation privacy choices/manage cookies methylation-specific pcr mgmt methylation status primary human neoplasia mgmt cgi methylation human astrocytic gliomas glioblastoma cell lines temozolomide versus procarbazine transcription factors predicted mgmt methylation respond chromatin structure alteration methylation hot spots commonly analysed region entire mgmt cgi transcription start site normal brain tissues neoplastic brain components german glioma network koichi ichimura nucleosome occupancy prediction promoter cpg island dna repair dna methylation modulate mgmt activity european economic area check access adenovirus-mediated overexpression induces replicative senescence exon/intron boundary eortc-ncic trial

Questions {❓}

Segal E, Widom J (2009) What controls nucleosome positions?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
         description:O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl DNA adducts such as those induced by alkylating agents. Loss of MGMT expression through transcriptional silencing by hypermethylation of its CpG island (CGI) is found in diverse human cancers including glioblastomas. Glioblastomas that have MGMT methylation respond to temozolomide, an alkylating agent, resulting in improved survival. Consequently, assessment of MGMT methylation has become a therapy response and prognostic indicator. However, it is not clear whether the region of the MGMT CGI commonly analysed is the critical region involved in transcriptional control. We measured methylation levels at each CpG site for the entire MGMT CGI using bisulfite modification and pyrosequencing, and compared them with MGMT mRNA expression in glioblastoma cell lines, xenografts and normal brain tissues (41 samples). Two critical regions were identified (DMR1 and DMR2). DMR2 encompasses the commonly analysed region and was always methylated when DMR1 was methylated. A luciferase reporter assay showed that substitutions of several specific CpG sites within DMR2 significantly attenuated the promoter activity of the MGMT CGI. Our results indicate that several CpG sites within DMR2 play a critical role in the transcriptional control of MGMT, making DMR2 the optimal target for methylation testing. However, given the highly variable patterns of MGMT methylation associated with transcriptional silencing observed in this region among the tumours in this study, methylation levels need to be measured at a number of individual CpGs within DMR2 to confidently predict transcriptional silencing and thus sensitivity to alkylating agents.
         datePublished:2011-02-03T00:00:00Z
         dateModified:2011-02-03T00:00:00Z
         pageStart:651
         pageEnd:661
         sameAs:https://doi.org/10.1007/s00401-011-0803-5
         keywords:
            MGMT
            Temozolomide
            Methylation
            Pyrosequencing
            Luciferase assay
            Nucleosome positioning
            Pathology
            Neurosciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig3_HTML.gif
         isPartOf:
            name:Acta Neuropathologica
            issn:
               1432-0533
               0001-6322
            volumeNumber:121
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Deborah S. Malley
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rifat A. Hamoudi
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sylvia Kocialkowski
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Danita M. Pearson
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vincent Peter Collins
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Koichi Ichimura
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
      description:O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl DNA adducts such as those induced by alkylating agents. Loss of MGMT expression through transcriptional silencing by hypermethylation of its CpG island (CGI) is found in diverse human cancers including glioblastomas. Glioblastomas that have MGMT methylation respond to temozolomide, an alkylating agent, resulting in improved survival. Consequently, assessment of MGMT methylation has become a therapy response and prognostic indicator. However, it is not clear whether the region of the MGMT CGI commonly analysed is the critical region involved in transcriptional control. We measured methylation levels at each CpG site for the entire MGMT CGI using bisulfite modification and pyrosequencing, and compared them with MGMT mRNA expression in glioblastoma cell lines, xenografts and normal brain tissues (41 samples). Two critical regions were identified (DMR1 and DMR2). DMR2 encompasses the commonly analysed region and was always methylated when DMR1 was methylated. A luciferase reporter assay showed that substitutions of several specific CpG sites within DMR2 significantly attenuated the promoter activity of the MGMT CGI. Our results indicate that several CpG sites within DMR2 play a critical role in the transcriptional control of MGMT, making DMR2 the optimal target for methylation testing. However, given the highly variable patterns of MGMT methylation associated with transcriptional silencing observed in this region among the tumours in this study, methylation levels need to be measured at a number of individual CpGs within DMR2 to confidently predict transcriptional silencing and thus sensitivity to alkylating agents.
      datePublished:2011-02-03T00:00:00Z
      dateModified:2011-02-03T00:00:00Z
      pageStart:651
      pageEnd:661
      sameAs:https://doi.org/10.1007/s00401-011-0803-5
      keywords:
         MGMT
         Temozolomide
         Methylation
         Pyrosequencing
         Luciferase assay
         Nucleosome positioning
         Pathology
         Neurosciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-011-0803-5/MediaObjects/401_2011_803_Fig3_HTML.gif
      isPartOf:
         name:Acta Neuropathologica
         issn:
            1432-0533
            0001-6322
         volumeNumber:121
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Deborah S. Malley
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rifat A. Hamoudi
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sylvia Kocialkowski
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Danita M. Pearson
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vincent Peter Collins
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Koichi Ichimura
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Neuropathologica
      issn:
         1432-0533
         0001-6322
      volumeNumber:121
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Deborah S. Malley
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Rifat A. Hamoudi
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Sylvia Kocialkowski
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Danita M. Pearson
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Vincent Peter Collins
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Koichi Ichimura
      affiliation:
            name:University of Cambridge
            address:
               name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
      name:Division of Molecular Histopathology, Department of Pathology, Level 3, Lab Block, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(135)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.34s.

LINK . SPRINGER . COM {}